Applied Therapeutics logo

Applied TherapeuticsNASDAQ: APLT

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

14 May 2019

Next earnings report:

06 March 2025

Last dividends:

N/A

Next dividends:

N/A
$1.15 B
-3%vs. 3y high
75%vs. sector
-vs. 3y high
-vs. sector
195.51
-3%vs. 3y high
100%vs. sector
-5.46 K
-7470%vs. 3y high
0%vs. sector

Price

after hours | Sat, 23 Nov 2024 00:30:42 GMT
$9.90+$0.63(+6.80%)

Dividend

No data over the past 3 years
$122.00 K$183.33 K
$122.00 K-$68.59 M

Analysts recommendations

Institutional Ownership

APLT Latest News

Applied Therapeutics (APLT) Upgraded to Buy: Here's What You Should Know
zacks.com29 October 2024 Sentiment: POSITIVE

Applied Therapeutics (APLT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Is Applied Therapeutics (APLT) Stock Outpacing Its Medical Peers This Year?
zacks.com24 September 2024 Sentiment: NEUTRAL

Here is how Applied Therapeutics Inc. (APLT) and Cardinal Health (CAH) have performed compared to their sector so far this year.

All You Need to Know About Applied Therapeutics (APLT) Rating Upgrade to Buy
zacks.com23 September 2024 Sentiment: POSITIVE

Applied Therapeutics (APLT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Applied Therapeutics: AdCom Decision Takes Govorestat Approval A Step Closer
seekingalpha.com19 September 2024 Sentiment: POSITIVE

Applied Therapeutics, Inc.'s stock surged nearly 70% yesterday after the news that the FDA will not hold an AdCom to discuss approval of AT-007 in galactosemia. AT-007 has shown clinical benefits in galactosemia and SORD deficiency, and its PDUFA for the former arrives at the end of November. With no AdCom, approval seems the likeliest outcome. Despite financial constraints, strong patient and HCP support suggest a successful commercial launch for govorestat, making Applied stock a “Buy” with expected valuation growth.

APLT Stock Soars 69% on Positive Update on Galactosemia Drug NDA
zacks.com19 September 2024 Sentiment: POSITIVE

Applied Therapeutics stock surges 69% as the FDA says that no advisory committee meeting is required to discuss the govorestat NDA for classic galactosemia.

Applied Therapeutics: FDA Stance Change For Advisory Panel Bodes Well For Review
seekingalpha.com18 September 2024 Sentiment: POSITIVE

FDA removes the need for an advisory panel to first give a recommendation review of Applied Therapeutics, Inc.'s govorestat for the treatment of patients with galactosemia. PDUFA date of November 28th, 2024, remains on track for the FDA to decide whether govorestat should be approved to treat patients with galactosemia. Pre-NDA meeting with FDA expected in 2nd half of 2024 to discuss possible administrative actions of NDA filing submission of govorestat for the treatment of patients with SORD deficiency.

Rare Disease-Focused Applied Therapeutics' Lead Candidate Govorestat Has Blockbuster Potential, Analyst Sees 140% Stock Upside
benzinga.com31 July 2024 Sentiment: POSITIVE

William Blair initiated coverage on Applied Therapeutics Inc. APLT, a late-stage development company focused on rare diseases such as galactosemia, SORD deficiency, and diabetic cardiomyopathy.

Applied Therapeutics: A Strong Buy With AT-007 Nearing Approval For Galactosemia
seekingalpha.com29 May 2024 Sentiment: POSITIVE

Applied Therapeutics is a clinical-stage biotech focused on treating symptoms of galactosemia in the central nervous system. Govorestat (AT-007) is in late-stage regulatory approval for galactosemia, with a PDUFA date set for November 2024. APLT holds $146.5 million in cash, ensuring a sufficient runway to FDA approval and initial product revenues by early 2025.

US FDA extends review of Applied Therapeutics' genetic disease drug
Reuters28 March 2024 Sentiment: NEGATIVE

The U.S. Food and Drug Administration has extended its review of Applied Therapeutics' experimental drug to treat galactosemia, a rare genetic metabolic disease, the company said on Thursday.

Applied Therapeutics (APLT) Surges 124% in a Month: Here's Why
Zacks Investment Research13 March 2024 Sentiment: POSITIVE

Applied Therapeutics (APLT) surges 124% in a month due to encouraging updates from two separate developmental programs for govorestat to treat different rare neurological indications.

What type of business is Applied Therapeutics?

Applied Therapeutics, Inc. is a biopharmaceutical company that develops products for the treatment of cardiovascular diseases, galactosemia, and diabetic complications. Applied Therapeutics, Inc. was founded in 2016 with headquarters in New York, New York. The portfolio of Applied Therapeutics includes three main products: AT-007 - being developed for the treatment of galactosemia, a rare and destructive pediatric metabolic disorder. AT-001 - a product with broad systemic impact and peripheral nerve permeability, being developed for the treatment of diabetic cardiomyopathy and fatal heart fibrosis. AT-003 - intended for the treatment of diabetic retinopathy or DR. DR is an ophthalmic disease that occurs in patients with diabetes, its treatment is limited to the use of expensive biologics requiring intravitreal injection.

What sector is Applied Therapeutics in?

Applied Therapeutics is in the Healthcare sector

What industry is Applied Therapeutics in?

Applied Therapeutics is in the Biotechnology industry

What country is Applied Therapeutics from?

Applied Therapeutics is headquartered in United States

When did Applied Therapeutics go public?

Applied Therapeutics initial public offering (IPO) was on 14 May 2019

What is Applied Therapeutics website?

https://www.appliedtherapeutics.com

Is Applied Therapeutics in the S&P 500?

No, Applied Therapeutics is not included in the S&P 500 index

Is Applied Therapeutics in the NASDAQ 100?

No, Applied Therapeutics is not included in the NASDAQ 100 index

Is Applied Therapeutics in the Dow Jones?

No, Applied Therapeutics is not included in the Dow Jones index

When was Applied Therapeutics the previous earnings report?

No data

When does Applied Therapeutics earnings report?

The next expected earnings date for Applied Therapeutics is 06 March 2025